Shukra Pharmaceuticals Ltd Share Price & Stock Analysis

Shukra Pharmaceuticals Ltd (BSE: 524632) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹3,613 Cr, it ranks #979 by market cap among the 6,197 Indian listed companies on FinBizNet, and #19 of 63 in Pharmaceuticals. At ₹82.26 (as of 16 Nov 2026), the share price is 3.0% below its 52-week high of ₹84.80 and 105.3% above its 52-week low of ₹40.06. The share price is up 97.9% over one year and up 73.2% over three months.

Key Metrics

Current Price₹82.26
Market Cap₹3,613 Cr
BSE Code524632
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio164.5
Return on Equity28.89%
Return on Assets18.29%
52-Week Range₹40.06 – ₹84.80
1-Year Price Change+97.9%
3-Month Price Change+73.2%
Beta (1Y)0.27
Dividend Yield0.01%
HeadquartersAhmedabad, Gujarat
Websitewww.shukrapharmaceuticals.com

Latest Quarterly Results — Q2 FY27

Revenue₹44 Cr
Net Profit₹13 Cr
Net Margin28.8%
EPS (Basic)₹0.29
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Shareholding and Delivery

Promoters held 51.15% of Shukra Pharmaceuticals Ltd's shares as of Sept 2026. Delivery averaged 30.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.

Products and Services

1. Pharmaceutical-This segment manufactures, exports, and markets various drugs and dosage forms.

Business Segments

1. Pharamaceutical Segment-100%

Shukra Pharmaceuticals Ltd vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Shukra Pharmaceuticals Ltd₹3,613 Cr164.528.89%₹44 Cr+97.9%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd is trading at ₹82.26, with a market capitalisation of ₹3,613 Cr.

Which sector does Shukra Pharmaceuticals Ltd belong to?

Shukra Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd has a P/E of 164.5 and a return on equity of 28.89%.

What is the stock symbol of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd is listed on the BSE under the scrip code 524632.

How has Shukra Pharmaceuticals Ltd's share price moved over the past year?

Shukra Pharmaceuticals Ltd's share price is up 97.9% over one year and up 73.2% over three months. Its 52-week range is ₹40.06 to ₹84.80.

What were Shukra Pharmaceuticals Ltd's latest quarterly results?

In Q2 FY27, Shukra Pharmaceuticals Ltd reported revenue of ₹44 Cr and net profit of ₹13 Cr, with basic EPS of ₹0.29 (consolidated, parsed from the company's exchange filing).

What is the promoter holding in Shukra Pharmaceuticals Ltd?

Promoters held 51.15% of Shukra Pharmaceuticals Ltd's shares as of Sept 2026.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.